Quick Summary
- Therapy: Apitegromab, a muscle-targeted monoclonal antibody
- Trial Outcome: Significant improvements in motor function for non-ambulatory SMA patients
- Regulatory Plans: Scholar Rock intends to submit for FDA and EMA approvals in early 2025
Scholar Rock recently announced promising results from its Phase 3 SAPPHIRE clinical trial, evaluating apitegromab in patients with spinal muscular atrophy (SMA), a rare neuromuscular disease. Apitegromab is a monoclonal antibody designed to inhibit myostatin—a protein that restricts muscle growth—increasing the potential for muscle maintenance and strength. The trial demonstrated meaningful improvements in motor function for non-ambulatory patients with Types 2 and 3 SMA, underscoring apitegromab’s potential to meet significant unmet needs in SMA management.
SAPPHIRE Trial Overview and Results
The SAPPHIRE trial was a randomized, double-blind, placebo-controlled study that included 156 children with Types 2 and 3 SMA who cannot walk. Participants, aged between 2 and 12, received either apitegromab at 10 mg/kg, 20 mg/kg, or a placebo in combination with standard SMA treatments such as nusinersen (Spinraza) or risdiplam (Evrysdi). Motor function was evaluated using the Hammersmith Functional Motor Scale Expanded (HFMSE), a standardized assessment for SMA patients.
The results showed a statistically significant improvement in HFMSE scores among those treated with apitegromab compared to the placebo group. Apitegromab was also well-tolerated, with no unexpected safety issues reported. Scholar Rock’s Chief Medical Officer, Dr. Jing Marantz, highlighted that these outcomes reinforce apitegromab’s potential to meaningfully enhance muscle function, benefiting daily activities and quality of life for SMA patients.
Next Steps and Regulatory Path
Scholar Rock plans to submit regulatory applications to both the FDA and the European Medicines Agency (EMA) in the first quarter of 2025. Apitegromab has already received several designations from both agencies, including Fast Track and Orphan Drug status from the FDA, as well as PRIME designation from the EMA. Scholar Rock aims to provide SMA patients and caregivers with an effective therapy that supports motor function, a need currently unmet by other available treatments.
The company will present detailed trial data at an upcoming medical conference in early 2025, which could further support apitegromab’s efficacy and safety profile as a promising SMA therapy.
References
